Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Sep 9;114(9):1214-1221.
doi: 10.1093/jnci/djac121.

Leadership Diversity and Development in the Nation's Cancer Centers

Affiliations
Editorial

Leadership Diversity and Development in the Nation's Cancer Centers

Caryn Lerman et al. J Natl Cancer Inst. .

Abstract

The capacity and diversity of the oncology leadership workforce has not kept pace with the emerging needs of our increasingly complex cancer centers and the spectrum of challenges our institutions face in reducing the cancer burden in diverse catchment areas. Recognizing the importance of a diverse workforce to reduce cancer inequities, the Association of American Cancer Institutes conducted a survey of its 103 cancer centers to examine diversity in leadership roles from research program leaders to cancer center directors. A total of 82 (80%) centers responded, including 64 National Cancer Institute-designated and 18 emerging centers. Among these 82 respondents, non-Hispanic White individuals comprised 79% of center directors, 82% of deputy directors, 72% of associate directors, and 72% of program leaders. Women are underrepresented in all leadership roles (ranging from 16% for center directors to 45% for associate directors). Although the limited gender, ethnic, and racial diversity of center directors and perhaps deputy directors is less surprising, the demographics of current research program leaders and associate directors exposes a substantial lack of diversity in the traditional cancer center senior leadership pipeline. Sole reliance on the cohort of current center leaders and leadership pipeline is unlikely to produce the diversity in cancer center leadership needed to facilitate the ability of those centers to address the needs of the diverse populations they serve. Informed by these data, this commentary describes some best practices to build a pipeline of emerging leaders who are representative of the diverse populations served by these institutions and who are well positioned to succeed.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Race and ethnicity of cancer center leaders. Cancer center directors who completed the survey reported their own race and ethnicity and the races and ethnicities of the leaders within their cancer centers. *20 cancer centers reported having no deputy director. A/PI = Asian or Pacific Islander; AI/AN = American Indian or Alaskan Native; NH = non-Hispanic; Other/Mixed = Other, mixed, or unknown race.
Figure 2.
Figure 2.
Gender of cancer center leaders. Cancer center directors who completed the survey reported their own gender and the genders of the leaders within their cancer centers. *20 cancer centers reported having no deputy director.
Figure 3.
Figure 3.
Perceived needs for leadership development programs. Cancer centers that had a leadership development program in place indicated what skills and abilities were cultivated in their programs. Categories are not mutually exclusive. CC = cancer centers.

Comment in

Comment on

References

    1. McDowell S, Ludwig Rausch S, Simmons K. Cancer research insights from the latest decade, 2010 to 2020. American Cancer Society; 2019. https://www.cancer.org/latest-news/cancer-research-insights-from-the-lat.... Accessed January 12, 2022.
    1. Kruger S, Ilmer M, Kobold S, et al.Advances in cancer immunotherapy 2019 – latest trends. J Exp Clin Cancer Res. 2019;38(1):268. - PMC - PubMed
    1. Ignatiadis M, Sledge GW, Jeffrey SS.. Liquid biopsy enters the clinic – implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297-312. - PubMed
    1. Bedard PL, Hyman DM, Davids MS, et al.Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet. 2020;395(10229):1078-1088. - PubMed
    1. Halbert CH, Allen CG, Jefferson M, et al.Lessons learned from the Medical University of South Carolina Transdisciplinary Collaborative Center (TCC) in precision medicine and minority men’s health. Am J Mens Health. 2020;14(6):1557988320979236. - PMC - PubMed

LinkOut - more resources